Verrica Pharmaceuticals VRCA 深 滬
已收盤 12-26 16:00:00 美东时间
8.16
-0.170
-2.04%
華盛通- 最 高8.48
- 今 開8.39
- 成交量 12.91万股
- 最 低 7.95
- 昨 收 8.33
- 總市值 7707.77万
- 52周最高 9.8212
- 市盈率 靜 --
- 換手率 1.37%
- 52周最低 3.28
- 委 比 -93.54%
- 總股本 944.58万
- 歷史最高 232.90
- 量 比 0.68
- 振 幅 6.36%
- 歷史最低 3.816
- 每 手 1
- 風險率 1.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
12-19 10:15
Brookline Capital Upgrades Verrica Pharmaceuticals to Buy, Announces $17 Price Target
Brookline Capital analyst Kemp Dolliver upgrades Verrica Pharmaceuticals (NASDAQ:VRCA) from Hold to Buy and announces $17 price target.
12-18 20:39
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) shares moved upwards by 38.7% to...
12-16 20:05
Verrica Pharmaceuticals Secures $50M Financing Deal
Verrica Pharmaceuticals ( ($VRCA) ) has shared an announcement. On November 23,...
11-25 00:59
Verrica Pharmaceuticals announces $50M PIPE financing
Verrica Pharmaceuticals (VRCA) said it has signed securities purchase agreements for a private investment in public equity (PIPE) that will raise about $50 million in gross proceeds before fees. The f...
11-24 21:40
Verrica Pharmaceuticals shares are trading higher after the company announced a $50 million private placement to retire debt and extend its cash runway.
Verrica Pharmaceuticals shares are trading higher after the company announced a...
11-24 21:01
Verrica Pharmaceuticals Q3 Adj. EPS $0.13 Beats $(0.68) Estimate, Sales $14.344M Beat $5.843M Estimate
Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $(0.68) by 119.26 percent. This is a 103.02 percent increase over losses of $(4.30) per
11-15 05:11
Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting
<p>Verrica Pharmaceuticals announced new data from its Phase 2 study of VP-315, an oncolytic peptide immunotherapy, demonstrating its potential to treat basal cell carcinoma (BCC). The study showed VP-315 reprograms the tumor microenvironment, increasing cytotoxic T-cell infiltration and reducing immunosuppressive T-regulatory cells. It achieved a 97% objective response rate and 51% complete histologic clearance rate, with no severe adverse event...
11-10 13:00
Verrica Pharmaceuticals Gets European Medicines Agency's Committee's Positive Feedback To File Marketing Authorization Application For YCANTH To Treat Molluscum Contagiosum
Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ:VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that the
10-21 04:09
Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union
The European Medicines Agency's CHMP has supported Verrica Pharmaceuticals' plan to submit a Marketing Authorization Application (MAA) for YCANTH® in the EU, based on successful Phase 3 studies in the U.S. and Japan. No additional Phase 3 trials are required. YCANTH, a cantharidin-based treatment for molluscum contagiosum, is already approved in the U.S. for adults and children aged two and older. Verrica plans to initiate regulatory submission a...
10-20 20:05
